Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

@article{Hagan2014CostAO,
  title={Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.},
  author={Liesl M Hagan and Mark S Sulkowski and Raymond F Schinazi},
  journal={Hepatology},
  year={2014},
  volume={60 1},
  pages={37-45}
}
UNLABELLED Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks. A 24-week course of SOF/RBV costs approximately US$169,000, with sustained virologic response (SVR) rates ranging… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 19 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Similar Papers

Loading similar papers…